Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Cyclophosphamide; Leukocyte cell therapy; Topotecan; Vincristine
- Indications Neuroblastoma
- Focus Adverse reactions
- 01 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 01 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 01 Feb 2017 Status changed from recruiting to active, no longer recruiting.